MorphoGene

MorphoGene was a Swiss private biotechnology company based in Morges focused on developing therapeutics for chronic wounds and dermatology applications. The company's core approach was to re-engineer growth factors with a high-affinity extracellular matrix-binding domain to improve local tissue retention and therapeutic efficacy at wound sites. Publicly available sources describe the business as early stage/preclinical and centered on pharmaceutical product conception, development, and commercialization. The company was founded in 2015 and was associated with Jeffrey Hubbell. Swiss registry-style sources indicate that the legal entity entered liquidation in 2025, so it does not appear to be an active operating biotech at present.